Skip to main content
. 2022 Apr 7;7(2):100445. doi: 10.1016/j.esmoop.2022.100445

Figure 1.

Figure 1

Kaplan–Meier survival curves examing the relationship between the Scottish Immunotherapy Prognostic Score (SIPS) and (A) progression-free survival and (B) overall survival in patients with non-small-cell lung cancer receiving first-line pembrolizumab monotherapy.